Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $466.79 --0%
EPS Growth %: +4.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +4.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of ($12.83), $1.13 worse than the analyst estimate of ($11.70). Revenue for the quarter came in at $2.65 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Vertex Pharma sees FY2024 revenue of $10.65-10.85 billion, versus the consensus of $10.762 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- BE Semiconductor (BESI:NA) (BESIY) PT Raised to EUR400 at Needham
- RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
